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ABSTRACT 
Lung cancer is a major chronic disease responsible for the highest mortality rate, 
among other types of cancer, and represents 29% of all deaths in Canada. The clinical 
diagnosis of lung carcinoma still requires a standard diagnostic approach, as there are no 
symptoms in its early stage. Therefore, it is usually diagnosed at a later stage, when the 
survival rate is low. With the recent advancement in molecular biology and 
biotechnology, a molecular biomarker approach for the diagnosis of early lung cancer 
seems to be a potential option. In this study, we aimed to investigate and standardize a 
promising Lung ,Cancer Biomarker by studying the aberrant methylation of two tumour 
suppressor genes, namely RASSFIA and RAR-B, and the miRNA profiling of four 
. commonly deregulated miRNA (miR-199a-3p, miR-182, miR-lOO and miR-221). Four 
lung cancer cell lines were used (two SCLC and two NSCLC), with comparisons being 
made with normal lung cell lines. Our results, we found that none of these genes were 
methylated. We then evaluated TP53, and found the promoter of this gene to be 
methylated in the cancer cell lines, as compared to the normal cell lines, indicating gene 
inactivation. We carried out miRNA profiling of the cancer cell lines and reported that 80 
miRNAs are deregulated in lung cancer cell lines as compared to the normal cell lines. 
Our study was the first of its kind to indicate that hsa-mir-4301, hsa-mir-4707-5p and 
hsa-mir-4497 (newly discovered miRNAs) are deregulated in lung cancer cell lines. We 
also investigated miR-199a-3p, mir-lOO and miR-182, and found that miR-199a -3p and 
mir-l00 were down-regulated in cancer lines, whereas miR-182 was up-regulated in the 
cancer cell lines. In the final part of the study we observed that mir-221 could be a 
putative biomarker to distinguish between the two types of lung cancer because it was 
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down-regulated in SCLC, and up-regulated in the NSCLC cell lines. In conclusion, we 
found four miRNA molecular biomarkers that possibly could be used in the early 
diagnosis of the lung cancer. More studies are still required with larger numbers of 
samples to effectively establish these as molecular biomarkers for the diagnosis of lung 
cancer. 
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INTRODuctION AND LITERATURE REVIEW 
Cancer is a chronic disease that causes death worldwide. In Canada, cancer is 
reported to be responsible for 29% of all deaths in males, and 24% in females (Canadian 
Cancer Society, 2011). It usually starts as a result of a mutation in the human genome, 
causing cells to grow in an uncontrolled manner, exhibiting abnormal cell division and 
differentiation. These mutations can lead to the activation of oncogenes or suppression of 
tumour suppressor genes (TSGs) (Bishop and Weinberg, 1996). There are several types 
of cancer, often named by the organ or tissue they affect, for example: lung, breast and 
prostate cancer. ~lthough' the underlying mechanism of all cancers is physiologically the 
same, involving uncontrolled cell growth and differentiation, different types of cancer 
_ vary in many other aspects involving genes, proteins, and biochemical parameters. 
Therefore, each cancer is diagnosed and treated differently. The molecular pathways of 
cancer progression require a thorough understanding to formulate an effective treatment 
against the disorder. 
Lung Cancer 
Lung cancer has the highest mortality rate among all other types of cancer. 
Individuals over the age of 45 and smokers are the more commonly affected. However, 
people who never smoke can also get lung cancer (Parkin et al., 2005). Lung cancer 
mainly falls under genetic diseases, which arise from either inheritance (Tokuhata et al., 
1963) or somatic alteration in specific genes (Minna, 1998). Lung cancer starts in the 
main bronchi or in any other part of the respiratory system, and gradually progresses to 
all areas of the respiratory system. In this case, it is called primary lung cancer, whereas 
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if the primary lung cancer -spreads to other organs/systems of the body, it is termed 
secondary lung cancer or metastatic cancer. 
Almost all human cancers involve genetic instability or mutations caused by 
various carcinogens that may affect the human genome at the chromosomal, nucleotide, 
or gene level. Similarly, development of lung cancer involves multiple factors, like 
chronic exposure to tobacco smoking, which can lead to genetic instability - an 
underlying factor in cancer formation (Lengauer et al., 1997). In the case of lung cancer, 
the abnormalities at the chromosomal level are found to be both numerical (aneuploidy) 
and structural (deletions and translocations). 
Pathogenesis 
Genetic mutations affect various cellular genes among which proto-oncogenes, 
tumour suppressor and DNA repair genes are the key factors, playing a central role in the 
progression of cancer. The activation of proto-oncogenes to oncogenes occurs due to 
point mutations, gene amplification, or chromosomal rearrangement. On the other hand, 
the inactivation of tumour suppressor genes occurs due to the loss of one allele, in 
combination with a point mutation or inactivation of the other allele (Fong et al., 1999). 
The role of altered gene expression and that of DNA repair genes are not fully established 
in the development of lung cancer (Fong et ai., 1999). 
Types of lung cancer 
The most common type of lung cancer which represents about 85% of all the 
cases of lung cancer is non-small cell lung carcinoma (NSCLC). NSCLC is divided into 
three subtypes: adeno, squamous cell and large cell carcinoma and it has four different 
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stages on the basis of size -and spread of the tumour (Molina et al., 2008). The most 
aggressive and the fast growing type of lung cancer is the small cell lung carcinoma 
(SCLC), but its occurrence is rare. SCLC includes small, mixed, and combined small cell 
oncogenic foci and is found in 20-25% of all lung cancer cases (Minna, 1998). SCLC 
exhibits itself in two stages: the limited and the extensive stage (Sher et al., 2008). The 
classification of lung cancer is dependent on the appearance of the tumour, as well as 
how it spreads and grows. Several studies have shown that the overall incidence of both 
types of lung cancer is higher in males than in females (Gloeckler Ries et al., 2003). Both 
types of lung cancer can share the same molecular lesions, such as inactivation or 
mutation of the _p53 gene, while other genes can be specific in one type of cancer only 
(Hanawalt et al., 2003). The multiple gene involvement makes the clinical progression of 
- the cancer complex. 
Risk factors 
Smoking is the most important risk factor for both types of lung cancer. 
Numerous studies have found an association between smoking and lung cancer, dating 
back to November 1951, when the first observations of mortality-associated deaths began 
(Doll and Peto, 1976). Smoking is responsible for the majority of lung cancer cases 
(Shopland et al., 1991). Cigarettes contain more than 4000 chemicals, out of which 50 are 
known carcinogens. Some of these carcinogens are tobacco-specific N-nitrosamines, 
benzene, pesticides and formaldehyde (IARC, 2002). The risk of getting lung cancer is 10 
to 20 times higher in smokers compared to non-smokers. The risk of the cancer 
development decreases when a person quits smoking. Cancer of the lungs may also affect 
non-smokers, which instead indicates the involvement of multiple factors in the 
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progression of lung cancer: Second hand (passive) smoking is responsible for killing 
3000 lung cancer patients each year in the United States (National Cancer Institute, 
2003). 
Asbestos is also considered a cause for the progression of lung cancer as it is has 
been found to be linked to carcinogenesis. People working in the asbestos industry, who 
are also cigarette smokers, have been found to have an increased mortality ratio of 53.2, 
whereas non-smokers exhibit a mortility ratio of 10.9 (where the mortality ratio is equal 
to the number of observed deaths in an exposed group divided by the number of expected 
deaths in a given population) (Hammond et al., 1979). This demonstrates the synergistic 
effect of smoking and asbestos exposure on lung cancer incidence rates. 
Environmental pollution can also have an impact on the incidence of lung cancer. 
Radon is an undetectable radioactive gas which is strongly associated with lung cancer. 
It can be released naturally in the environment, which increases the risk of lung cancer 
development by 10- 20% (Barros-Dios et al., 2002). Several studies have also found a 
link between radon exposure and smoking in lung cancer development (Hornung et aI., 
1987). 
Familial history and inheritance playa significant role in the development of lung 
cancer, with a 2.4-fold increase in susceptibility in the case of first-degree blood relatives 
(Amos et al., 1992). Women with a positive family history are more likely to develop the 
disease than males (Wu et al., 1996). Persons with a familial history of cancer, when 
exposed to risk factors, show an increase in susceptibility to cancer. 
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Current diagnostic metnods and their limitations 
Lung cancer is difficult to diagnose clinically, as there are no symptoms in its 
early stage, and it has non- specific symptoms in its later stage (Read et a!., 2006). The 5-
year survival rate for a lung cancer patient diagnosed in an early stage is around 60%, 
while it is 4- 5% if the patient has been diagnosed in a later stage. That means 
diagnosing lung cancer at an early stage can greatly affect the patient's survivability 
(Mountain et al., 1997). The outcome of a patient with lung cancer is often poor because 
current detection methods are not effective in detecting cancer in its early stages, 
therefore the cancer ha~ already metastasized at the time of diagnosis, leading to 
difficulty in treatment. The metastasis of the lung cancer exhibits a faster and complex 
progression which makes the prognosis of the cancer difficult (Mountain et al., 1997). 
X-ray radiography was the first test used in the screening of lung cancer. In fact, 
lung cancer mortality rates were the same by using x-ray alone or when it was combined 
with sputum cytology (Prorok et at., 1984). Chest radiography or sputum cytology are the 
most common methods that have been used in the early diagnosis of lung cancer. 
However, it was found that there were no improvements made in cancer mortality rates 
by using these techniques (Rossi et at., 2005). Although sputum cytology is a less 
invasive method of diagnosis, it can give negative results in about 10% of lung cancer 
patients if the tumour was localized in the upper respiratory tract (Lam et at., 2001). 
Computer tomography (CT) scans have been proposed as a technique to 
overcome the limitations in using sputum cytology. This technique can detect a tumour of 
0.5 cm, whereas x-ray can only detect a tumour larger than 3cm (Kaneko et al., 1996). 
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N one of the aforementioneo screening methods for lung cancer are entirely reliable, 
therefore they give rise to high false positive and false negative rates (Kuzniar et al., 
2004). Moreover, many of these methods are invasive, and have limitations in detecting 
the disease in its early stage. Early stage diagnosis of cancer requires molecular 
biomarkers, which are considered non-invasive, as well as conclusive in diagnosis. These 
markers must also be specific in the early detection of cancer, so that metastasis can be 
prevented, so treatments will be much more effective (Cho and Sung, 2009). 
New Approach for the Early Detection of Lung Cancer 
Cancer biomarkers 
A biomarker is a substance or a molecule that can help to distinguish any changes 
In the physiology of a normal cell. Biomarkers can be divided into several types 
depending on the area of interest, such as genetic, epigenetic, and proteomic (Sung and 
Cho, 2008). These different biomarkers will help in the prediction and early detection of a 
disease, which will determine the outcome of a patient, as well as the selection of an 
effective treatment. They can also be used for monitoring disease recurrence (Greenberg 
et al., 2007). Overall, biomarkers must assist in the early diagnosis, treatment and 
prognosis determination of a disease. 
The discovery of a lung cancer biomarker is now emerging as the most important 
and advanced method for diagnosis, as it allows for early detection of the most common 
types of lung cancer. Early detection of NSCLC has been found to enhance the 5 year 
survival rate from 15% to 80% (Mulshine et al., 2005). Biomarkers can play an important 
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role not only in the diagnosis of a disease, but also in the treatment. However, other 
methods (for example, surgery) are also available for treatment of the carcinoma if 
diagnosed in an early stage (Cortese et aI., 1983). Some studies have shown that using 
surgery to treat lung cancer increases the survival rate of 70% of patient to 5 years or 
more, compared to patients who did not have surgery (Flehinger et al., 1992). 
A biomarker should have several characteristics in order to be effective. First, it 
should be able to distinguish between normal and abnormal tissues with a significant 
difference found between the two (i.e. it should have a high sensitivity and specificity). 
Moreover, the method used for collection of a patient's sample has to be less invasive 
than gold standard techniques (Field et al., 2001). Biopsy is important, and already in use 
for the detection of lung cancer. However, it is invasive for the patient and difficult for 
the physician. Furthermore, the methods that should be used in biomarker discovery 
should be cheap, with a high efficiency (cost effective). Finally, the biomarker should 
also target treatments to make them more effective (Brambilla et al., 2003). Biomarkers 
must exhibit two basic features, efficacy and the specificity to the disorder, so that it can 
be effectively used in the diagnosis and mitigation of the disease. 
Current lung cancer biomarkers 
Patients with cancer exhibit elevated levels of circulating DNA in their plasma 
and serum as compared to healthy individuals (Xue et al., 2006), which is mainly due to 
apoptotic or necrotic tumour cells (Jahr et al., 2001). This circulating DNA exhibits 
altered features that results from genetic and epigenetic changes (Sozzi et al., 1999). 
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One of the most common and early genetic changes in lung cancer is a loss of the 
chromosome 3p (Cuda etal., 2000), which has been found in nearly 88% of all 
circulating DNA in the plasma of lung cancer patients (Xue et al., 2006). Mutations in 
p53 and K-ras are also common in lung cancer. These mutations have been found in the 
circulating DNA of 27% and 20-30% of all lung cancer patients, respectively (Aviel-
Ronen et al., 2006). Most of the genetic-based cancer biomarkers discovered up until 
now were either related to the activation of oncogenes, or the inactivation of TSGs 
(Brambilla et al., 2003). Several TSGs are present in chromosome 3p, therefore, any loss 
or deletion in this chromosome will inactivate these genes (Zabarovsky et al., ~002). 
Epigenetic changes are an alternative mechanism that also induces the activation 
or inactivation of both oncogenes and TSGs (Chung et al., 1995). The methylation status 
of an altered allele of a TSG can be a useful biomarker in all types of cancer. There are 
several well known TSGs that have been found to be methylated in lung cancer, such as 
O(6)-methylguanine- DNA methyltransferase (06-MGMT), death associated protein 
(DAP)-kinase, Cyclin-dependent kinase 2A (p16), Adenomatous polyposis coli (APC) 
and Ras association domain family member 1 (RASSFl) (Zochbauer et al., 2002). 
Today, many researchers are focusing on protein biomarkers, because the level of 
the messenger RNA in the cell does not always reflect the level of protein. Carcino 
embryonic antigen (CEA) is one of the proteins that have been found to be elevated in 
lung cancer patients (Molina et al., 2005). CEA is used in combination with CYFRA, 
with the concentrations of each protein being monitored in the sera of patients to improve 
lung cancer diagnosis. Table 1 shows several cancer biomarkers that have been used 
clinically in different types of cancer. 
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Table 1: Cancer biomarkers -that are currently in clinical use. 
CEA 
Several cancers 
including colorectal, 
lung, breast, liver, 
pancreatic, 
. bladder 
Determine recurrence, 
Monitor treatment 
efficacy 
23 
Lung Cancer Biomarker 
Gold and Freedman, 1965 
Hadeel Zamakhshari Lung Cancer Biomarker 
Out of all these biomarkers, not a single biomarker is specific enough for the 
clinical diagnosis of the lung cancer of interest, and its characterisation for an effective 
treatment. One major constraint of using these biomarkers is the general lack of detailed 
clinical data using a large sample enough sample size to properly assess the biomarker's 
potentiality in the exact diagnosis of the lung cancer state, or the specific type of cancer. 
Similarly, the biomarkers should be tested extensively -in all other types of cancer to 
evaluate their effectiveness in each cancer diagnosis and treatment. This will be followed 
by the use of a specific lung cancer biomarker, through new technology for lung cancer 
sUbtypes. Combining them together will make them useful in clinical practice for cancer 
diagnosis (Sung and Cho, '2008). 
Gene Hypermethylation 
Epigenetic changes are also important hallmarks of cancer. The major epigenetic 
change that occurs in the human genome is cytosine methylation which is found in the 
CpG regions of genes (Esteller et al., 2002). The allocation of the CpG region is not the 
same in different genes. A rich CpG region is known as a CpG island, which is 
unmethylated in normal tissues (Bird, 1986). There are mainly four genes in the human 
body that can be found methylated in a normal state. These are the genes specific for 
tissue types, genes specific for germline, imprinted genes and genes on the X-
chromosome in females (Baylin et al., 1998). 
Methylation affects the transcription of genes and causes gene silencing by 
several mechanisms. First, methylation interferes with specific transcription factors in 
their binding sites at the promoter. For example, the binding of the transcription factors 
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E2F, AP-2 and CREB have been found to be inhibited by the addition of the methyl 
group in their recognition sequence (Tate and Bird et al., 1993). Moreover, some 
transcriptional repressors such as MeCPl and MeCP2 bind directly to the methylated 
DNA (Prokhortchouk and Hendrich, 2002). Second, chromatin structure and histone 
modifications, which have an impact on gene expression, are affected by methylation 
(Bender et al., 1998). Finally, histone methylases can cause the lysine in histones to 
become methylated, as a result, the chromatin structure and gene expression are also 
altered (Fahrner et af., 2002). 
If methylation of a CpG island is found outside of the 5' region (which includes 
the promoter, exon 1 and untranslated region), it will not affect the transcription of the 
RNA associated with that gene (Jones, 1999). It is not yet clear why some genes become 
methylated in tumour cells and others are free from methylation (Baylin et al., 2006). 
Nevertheless, it is common in most tumours, and can be specific to some types of cancer 
(Costello et al., 2000). For instance, the gene p16 and RASSFI are found to be 
methylated in most tumour types (Burbee et ai., 2001 and Merlo et al., 1995). However, 
the Glutathione S-transferase PI (GSTP1) gene has been found to be methylated in 90% 
of prostate cancer cases, and unmethylated in leukemia (Lee et al., 1994). Table 2 shows 
the genes which are commonly methylated in different human cancers. 
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Table 2: The commonly . methylated genes in human cancer and their role in tumour 
development (Das and Singal, 2004). 
Gene 
DAPKI 
Role in tumour development 
Calcium/calmodulin-dependent enzyme 
that phosphorylates serine/ threonine 
residues on proteins; Suppression of 
apoptosis 
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Site of tumour 
Lung 
Reference 
Harden et 
al., 2003 
Hadeel Zamakhshari 
hMLHl 
pIS 
Defective DNA mismatch repair and gene 
mutations 
Unrestrained entry of cells into activation 
and proliferation 
Lung Cancer Biomarker 
Colon 
Gastric 
Endometrium 
Ovarian 
Leukemia 
Lymphoma 
Squamous cell 
carcinoma, lung 
Veigl et ai., 
1998 
Waki etai., 
2002 
Kondoet 
ai., 2000 
Melki et ai., 
1999 
Garcia et 
al., 2002 
Abbreviations: APe, adenomatous polyposis coli; BRCAl, breast cancer 1; CDKN2A1p16, 
cyclin-dependent kinase 2A; DAPKl, death-associated protein kinase 1; ER, estrogen 
receptor; GSTPl, glutathione S-transferase Pi 1; hMLHl, Mut L homologue 1; MGMT, 0-6 
methylguanine-DNA methyltransferase; RASSFIA, Ras association domain family member 
1; Rb, retinoblastoma; VHL, von Hippel-Lindau; GIT, gastrointestinal tract; NHL, non-
oma. 
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The genes responsibfe for regulating the cell cycle (P16, Rb), DNA repair genes 
(MGMT), and genes regulating metastasis, drug resistance and apoptosis (DAPK) are the 
most commonly susceptible to hyper methylation. The Rb gene was the first TSG 
described to be inactivated by hyper methylation (Ohtani-Fujita et al., 1993). 
Hypomethylation is another form of methylation that has been found in malignancies 
(Kim et al., 1994). It can lead to oncogene activation (Feinberg et al., 1983), instability of 
chromosomes (Tuck-Muller et al., 2000) or activation of latent retrotransposons (Alves et 
al., 1996). The hypomethylation of oncogenes has been reported in many human 
tumours. Ras genes are the most well-known oncogenes with a reduced level of 
methylation in many types of cancer (Feinberg et al., 1983). The activation of the C-myc 
gene was also reported in several studies (Stephenson et al., 1993). Figure 1 shows the 
- role ofhypermethylation and hypomethylation in cancer. 
lIJpomihyIation .-
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Figure 1: Models for the role of DNA methylation in cancer (Laird et al., 1996). 
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Gene methylation can also be . used as a qualitative marker. Death-associated 
protein kinase (DAPK) is a metastasis repressor, and its methylation in lung cancer can 
be used as an indicator of metastatic potential/virulence of the tumour (Tang et at., 2000). 
Other methylated genes may also be used as a predictor of an individual's response to 
treatment, such as MGMT, which helps in determining if the patient will benefit from 
chemotherapy or not (Esteller et al., 1999). 
Epigenetic alterations are reversible, and as a result, they can be used in following 
a cancer treatment by observing the reactivation of already silenced genes. Two 
methyltransferase inhibitors, 5- azacytidine and 5-aza-2-deoxycytidine, can be'used tore-
express silenced genes (Baylin et aI., 2001). Nevertheless, they are quite toxic. To 
overcome this limitation, a small dose of these drugs has been used in combination with 
histone-deactylase inhibitors (Cameron et aI., 1999). By using this combination, a 
promising approach has been found not only in reactivation of genes, but also in killing 
affected cells (Bovenzi et al., 2001). 
Gene promoter hypermethylation has recently been used as a new approach for 
the detection of lung cancer because it can be detected easily in tissue and in bodily 
fluids. In addition, DNA analysis is a relatively easy approach, as DNA has higher 
stability than protein and RNA. About 15-80% of functional genes are methylated at an 
early stage in lung cancer (Belinsky et aI., 2004). In 1999, screening for promoter 
hypermethylation in the sera ofNSCLC patients began (Esteller et al., 1999). 
The methylated genes in SCLC and NSCLC are not always the same. This can 
help in distinguishing the two types of lung cancer from each other (Toyooka et al., 
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2001). Tsou (2002) found tliatmore than 40 genes were hypermethylated in lung cancer, 
with the most common being RAR-f), APC, CDRl3, and RASSFlA (Table 3). 
Several factors have been shown to contribute to the sensitivity and specificity of 
DNA methylation biomarkers: the specific gene type of cancer under study, the type of 
specimen used, and the methylation detection technique utilized (Laird et al., 2003). 
Several powerful techniques have been used in the detection of DNA methylation. 
Table 3: Frequent methylated genes in both types of lung cancer (Zochbauer-Miiller et 
al., 2002). 
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Methylation detection techniques 
Methylation-sensitive and -insensitive restriction enzyme digestion is the oldest 
method that has been used to screen for methylation. This method is considered a 
sensitive method because of the use of PCR, which has the ability to amplify extremely 
low concentrations of DNA. Depending on the restriction enzyme used, it will cleave the 
strand of DNA only if the restriction site is methylated, or not methylated. Next, primers 
flanked with the restriction site will be used to amplify the digested DNA. This method 
can give a false positive or false negative result, however, due to incomplete digestion. It 
can also give inconclusive results depending on the presence of a CpG site. However, this 
method can be used for primary DNA methylation screening (Momparler and Bovenzi, 
2000). 
In 1992, a new technique was discovered for methylation screening, which was 
based on bisulfite sequencing. Frommer et al. (1992) were able to convert all of the 
unmethylated cytosines within a DNA fragment to uracil by using sodium bisulfite 
treatment. Next, they used a set of specific primers which amplified the uracil as thymine, 
and the methylated cytosines remain the same. Finally, the amplified fragments were sent 
for sequencing. Harrison et al. (1998) reported that the cytosines are resistant to this 
treatment. 
Methylation-specific PCR is another method that uses bisulfite treatment for 
methylation analysis. It was first described by Herman et al. (1996). By using PCR, the 
converted uracil will replicate as thymine. Therefore, pairs of primers were designed 
either complementary to the cytosine or to the converted thymine. The amplified product 
will reveal if the DNA was methylated or not depending on the primer used. This method 
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can give false positives as a-result of incomplete conversion of the cytosines, or from the 
selected primers. 
microRNA 
Several small RNAs have been discovered to be functional RNA in the past 20 
years. DNA is transcribed into messenger RNA, which is translated into functional 
proteins. Ribosomal RNA and transfer RNA are both important, and have a role in 
protein synthesis (Sassen et al., 2008). In 1993, small non-coding RNA called microRNA 
(miRNA) was discovered by Victor Ambros and his colleagues Rosalind Lee and Rhonda 
Feinbaum (Lee et at., 1993). These miRNAs bind to mRNAs in the 3' untranslated 
regions (3'UTR) and regulate their expression (Ruvkun, 2001). miRNA plays an 
important role in cell functions, such as differentiation, proliferation, metabolism and cell 
death, in spite of their extremely low concentrations (Ambros, 2003). miRNA has been 
found to be one of the important regulators of genes in humans, as they regulate more 
than 30% of the human protein-coding genes (Rajewsky, 2006). 
miRNA formation begins in the nucleus by type II RNA polymerase to form a pri-
miRNA (Cai et at., 2004). The pri-miRNA is then cleaved by an RNase III endonuclease 
called Drosha into a hairpin precursor miRNA (pre-miRNA) which is 60-100 bps long. 
This pre-miRNA is then transported into the cytoplasm by exportin 5, and is processed by 
a second RNase III endonuclease (Dicer) into an 18-25 bp mature double-stranded 
miRNA (Yi et al., 2003). The mature miRNA will incorporate with Argonaute (Ago) 
proteins, forming anRNA-induced silencing complex (RISC), which causes post-
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transcriptional gene silenc!ng of its target genes either by degradation or translational 
inhibition (Liu et aI., 2004) (Figure 2). 
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Figure 2: The biogenesis of micro RNA (Teagu et aI., 2010). 
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The studies carried out on miRNA have shown many interesting and valuable 
features, indicating their potential application in the treatment of human cancer. The 
studies carried out in the roundworm C. elegans and the fruit fly Drosophila have shown 
that miRNA plays a critical role in the regulation of cell proliferation and programmed 
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cell death (apoptosis) (Brennecke et al., 2003). When studies were carried out on human 
miRNA, it was found that many miRNA genes were located in regions of the human 
genome that are commonly altered (amplified or deleted) in human cancer (Calin et al., 
2004). Moreover, it was also noticed that the expression ofmiRNA was widely disturbed 
in malignant cells, compared to normal cells (Gaur et aI., 2007). Although, these early 
observations indicate the potential role of miRN A in cancer development, it is still not 
known whether these alterations in miRNA expression cause cancer, or they arise as a 
result of cancer development. Many studies have found a link between miRNAs and 
cancer development. These miRNAs can be found in Table 4. 
Calin et al. (2002) reported the role of miRNA in cancer, specifically in 
lymphocytic leukemia (CLL). They focused on the most common chromosomal 
abnormality known to lead to leukemogenesis, a deletion on chromosome 13. They 
discovered that miR-15 and miR-16 were located in this region. The expressions of the 
two miRN As were measured in normal tissues and compared to levels found in LLC 
patient's blood samples. In 68% of the cases, miR-15 and miR-16 were down-regulated 
or absent, suggesting their involvement in the pathogenesis of CLL. 
Later, He et al. (2005) and O'Donnell et al. (2005) reported an interaction 
between mir-17 -92, and the Myc oncogenic pathway. In addition, the relation between 
let-7 miRNA and the RAS proto-oncogene has been reported (Johnson et ai., 2005). 
These different studies were first to explain the involvement of miRNA in cancer 
pathogenesis. 
34 
Hadeel Zamakhshari Lung Cancer Biomarker 
Table 4: Lung cancer-related microRNAs (Megiomi et at., 2011). 
miR-196a2 Up 
miR-21 Down K-RAS, cell proliferation 
35 
rsl1614913CC genotype 
associated with increased 
risk of lung cancer and 
reduced overall survival 
Associated with tumour 
stage, cancer-specific 
mortality, and disease-free 
survival in NSCLC· able 
Hadeel Zamakhshari 
miR-99b Up 
Lung Cancer Biomarker 
to discriminate lung 
cancer from healthy 
controls 
Higher levels in AC than 
inS CC 
NSCLC: non-small cell lung carcinoma; AC: adenocarcinoma; SqCC: squamous 
cell carcinoma. 
There are several mechanisms involved in miRNA's ability to regulate cancer. 
One mechanism is miRNA deregulation, such as up-regulation of miRNA expression as a 
result of amplification of its gene locus, or down-regulation of the miRNA expression 
due to chromosomal deletion (He et at., 2005 and Ca1in et at., 2002). Epigenetic 
regulation of miRNAs has also been found in some cancer cases. For example, promoter 
hypermethy1ation of mir-124a has been found to be inactivated in several tumours 
(Lujambio et at., 2007). The loss of miRNA binding sites in some target genes can 
regulate miRNA through disrupting the interaction between miRNA and its target (Mayr 
et ai., 2007). Thomson et at. (2006) reported that miRNAs can be regulated by their 
processing enzymes. They found that regulation of miRNAs during their processing 
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steps, such as the altered function of -the enzyme Drosha (an . RNase III endonuclease), 
can lead to the down-regulation ofmiRNA in human cancer (Thomson et aI., 2006). 
miRN As can also function as TSGs or oncogenes, depending on the target gene 
that they inhibit. mir-21 is an example of a miRNA that promotes oncogenesis. It is over-
expressed in several types of tumours, and targets different tumour suppressor genes with 
roles in proliferation or apoptosis (Si et aI., 2007). Other miRNAs promote homeostasis 
when their expression is up-regulated such as let-7. Its expression has been known to be 
down-regulated in several tumours, which promotes tumour growth (Zhang et al., 2007). 
Several well-established techniques that have been used to study the expression of 
mRNA and DNA have been modified to include miRNA, such as northern blot and DNA 
- microarray, respectively (Valoczi et aI., 2004 and Castoldi et al., 2006). Microarrays 
have allowed for the analysis of multiple miRNA expression levels among various 
samples (Nelson et al., 2004). Quantitative real-time polymerase chain reaction (RT-
qPCR) has been used in parallel with microarray. They allow detection ofmiRNA using 
very small inputs, such as a single cell (Tang et al., 2006) or they can be used to validate 
the microarray results. 
The expression profiles of miRNA have been found to be different in certain 
human cancers, based on their developmental origin, which makes them promising 
biomarkers for cancer diagnosis. Lu et al. (2005) evaluated the expression profile of 217 
miRNAs in 17 tumours of unknown origin. They found that based on their expression 
profile, they were able to correctly diagnose 12 of these tumours, whereas the expression 
profile of 16,000 mRNAs were not able to classify any of these tumours (Lu et aI., 2005). 
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miRNA can be useful for clinical diagnosis because they also show high stability. 
Exosomes · are multivesicular bodies resulting from endosomes fusing with the cell 
membrane, "pinching off', and leaving the cell. Microvesicles are similar, smaller 
vesicles that bud off the parent cell, however they are not endocytic in nature (Miranda et 
al., 2010). Both exosomes and microvesicles are secreted by many cell types, and they 
often contain RNA originating from their parent cell. These vesicles have been found to 
protect miRNA from nucleases, making them important sources of miRNA discovery 
(Taylor et al., 2008). miRNA can be found in all bodily fluids, and they have unique 
expression profiles for each body fluid (Weber et al., 2010). One limitation to miRNA 
analysis is that miRNA often exists in low quantities in bodily fluids, resulting in low 
miRNA isolation yields. However, reliable quantitation can be done using RT-qPCR 
- (Yendamuri and Kratzke, 2011). 
Aim of This Study 
The primary aims of this study are three folds: First, to analyse and contrast 
miRNA molecules found in human lung cancer and normal human cell lines. Second, is 
to examine differential genomic DNA methylation patterns in lung cancer and normal 
human cell lines. And third, is to identify any potential biomarker for the early diagnosis 
of Lung Cancer. 
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MATERIALS AND METHODS 
Cell Culture 
Cell Lines and Maintenance 
This study was aimed at comparing four human lung cancer cell lines and a 
normal lung cell line (CCD-8LU) obtained from the American Type Culture Collection 
(ATCC). Among the cancer cell lines, two were SCLC (HI688 and H164) and the other 
two were NSCLC (H522 and A549). All the cell lines were collected from 50-60 year old 
male, Caucasian patients, before therapy. All cell lines were maintained in 150 mm Petri 
cell culture dishes and ,?ultured in their specific medium, i.e. the normal cells were 
cultured in ATCC-formulated Eagle's Minimum Essential Medium while the Lung 
cancer cell lines HI688, H164 and H522 were cultured in ATCC-formulated RPMI-1640 
Medium. Finally, the lung cancer cell line A549 was cultured in ATCC-formulated F-
12K Medium. All cells were incubated at 37°C with 5% CO2 and 96% relative humidity 
after addition of 5% (v/v) of fetal bovine serum. 
All cell lines were passed after they became 90% confluent by, addition of 0.25% 
(w/v) trypsin -0.53 mM EDTA. First the mediums were removed by aspiration, followed 
by washing with 6 ml of phosphate buffered saline (PBS). Four millilitre volumes of the 
EDTA-trypsin were added to the plate after aspirating the wash solution. Two to five 
minutes later the cell layer was dispersed by tapping the plate, and 6 ml of new medium 
was added to inactivate the trypsin. The suspension was split in a ratio of 1:3. 
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Cell line freezing and thawing 
At 90% confluence, the cells were lifted by -EDT A -trypsin and -pelleted by 
centrifugation at 125 x g for 10 minutes. The cell pellet was then resuspended in 4 ml 
new medium, supplemented with 5% (VN) DMSO and then stored at -70°C. The cells-
were thawed by agitation in a 37°C water bath for only 2 minutes. The vial contents 
were then transferred to a petri dish and diluted with 20 ml of their recommended 
medium, which was placed in the incubator for 10 minutes prior to the addition of cells. 
The DMSO was removed by changing the medium after 24 hours to avoid its cytotoxic 
effect. 
Isolation of Nucleic Acids from Cell Lines 
DNA, RNA and miRNA isolation 
Using Norgen's All-in-One Purification Kit (Norgen Biotek Corp.), RNA, DNA 
and miRNA were isolated from all cell lines following the manufacturer's protocol. 
Nucleic acids were also isolated from 293 and HeLa cells as positive controls. Briefly, 
350 JlL of Lysis Solution (with 0.01 % ~-mercaptoethanol) was added directly to the 
culture plates, following medium removal. Culture dishes were tapped and swirled, 
allowing cells to lyse for 5 minutes. The lysate was then transferred to a 1.7 mL 
microcentrifuge tube. Fifty microlitres of 95% ethanol was then added to the lysate, and 
vortexed for 10 seconds. The lysate was then bound to an All-in-One Column, and spun 
at 14000 rpm for 1 minute. The flowthrough was retained at kept and -20°C until 
subsequent miRNA purification. The column was then washed 3 times with 400 JlL of 
RNA Wash Solution, with 1 minute of centrifugation, then spun empty to dry for 2 
minutes. Both washing and drying steps took place at 14000 rpm. Large RNA species 
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were then eluted in 50 ~L RNA Elution Solution, with the column placed in a fresh 1.7 
mL Elution Tube. The column was then centrifuged for 2 minutes at 2000 rpm and 1 
minute at 14000 rpm. Following RNA purification, DNA was purified using the same 
All-in-One column. Briefly, 500 ~L of gDNA Wash Solution was added to the already-
processed column, and centrifuged for 1 minute at 14000 rpm, and once the flowthrough 
was discarded, the column was spun empty for 2 minutes at 14000 rpm to dry the 
column. Genomic DNA was then eluted in 100 ilL of gDNA Elution Buffer, with the 
column placed in a fresh 1.7 mL microcentrifuge tube. The elution step once again 
involved a 2-minute centrifugation at 2000 rpm, followed by 1 minute at 14000 rpm. 
Finally, miRNA was purified on the microRNA Enrichment column using the 
flowthrough from the RNA binding step. Briefly, 200 ilL of 95% ethanol was added to 
. the RNA flowthrough, and vortexed for 10 seconds. The entire contents were passed 
through a microRNA Enrichment column by centrifugation at 14000 rpm for 1 minute. 
The column was then washed twice with 400 ~L RNA Wash Solution, and centrifuged 
for 1 minute at 14000 rpm for each wash. The column was then dried for 2 minutes at 
14000 rpm. miRNA was then eluted in 50 ilL of RNA Elution Solution, with the column 
placed in a fresh 1.7 mL micro centrifuge tube. miRNA elution took place for 2 minutes at 
2000 rpm followed by I minute at 14000 rpm, as with the gDNA and large RNA elutions. 
RNA, miRNA and gDNA were all stored at -20oe until further processing. 
Nucleic acid quantification 
The nucleic acids were quantified and their absorbance was measured at 260nm 
and 280nm using the NanoVue™ spectrophotometer. The value A260lA280 was used to 
check the purity of the samples which is supposed to be between 1.8 and 2.1. 
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Restriction Enzyme-Digestion, Inactivation and DNA Cleaning 
Dpnl, HpaII and HhaI restriction enzymes were obtained from New England 
Biolabs. The digestion was carried out according to manufacturer's instructions. Ten units 
of the enzyme were used to digest the DNA in a 20 ilL reaction overnight in a 37°C 
incubator. HpaII was then heat-inactivated at 80°C for 20 minutes, but HhaI required 
enzymatic reaction clean up, as it could not be thermally inactivated. Enzymatic reaction 
clean-up was conducted using Norgen Biotek's Enzymatic Reaction Clean-Up Kit 
(Norgen Biotek Corp.). The protocol was followed as per manufacturer's product insert. 
First, 5 volumes of binding solution was added to each reaction mixture, and the samples 
were added to the column to be spun at 14000 rpm for 1 minute. One wash step was 
required, which involved 500 ilL Wash Solution spun at 14000 rpm for 2 minutes. 
Samples were eluted in 50 JlL of Elution Buffer, spun at 2000 rpm for 2 minutes, and 2 
additional minutes at 14000 rpm. 
peR 
Using the purified DNA (aforementioned), polymerase chain reaction (PCR) was 
performed using the Bio-Rad iCycler according to the standard technique explained by 
Mullis et al. (1996). The forward (F) and reverse primers (R) used in all PCR 
amplifications are listed in Table 5. Using 0.12 ilL of each primer, 1ng or less of the 
DNA template, 0.2 ilL of all four dNTPs, 2 ilL of lOX PCR buffer, 500mM KCI, 1% 
Triton X-100, 0.1 ilL of Taq polymerase enzyme and dH20, 20 ilL reaction mixtures 
were made. The reaction was then initially denatured at 94°C for 3 minutes, and cycled 
between denaturation (94°C for 15 seconds) strand annealing (for 15 seconds) to allow 
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annealing of primers to template and then polymerization temperature (72°C for 1-2 
minutes) to allow extension of primers to form the new strand. After PCR optimization, it 
was observed that after 30 cycles, sufficient amplification was achieved. The annealing 
temperatures for each primer differed, with GAPDH annealing at 51°C, RASSFIA at 
59°C, RAR-P at 61°C, and TP53 at 60°C. 
Table 5: The list and sequence of different peR primers that have been used in this study. 
Gene Forward primer 
Gel Electrophoresis 
DNA gel electrophoresis 
Reverse primer 
The PCR amplified samples as well as genomic DNA samples isolated using the 
All-in-One Purification kit were then analyzed by agarose gel electrophoresis according 
to the method explained by Sambrook et al. (1989). Ten microlitres of each genomic 
DNA elution was run on a IX TAB 1 % agarose gel. Twenty microlitres of the PCR 
amplified samples were run on a IX TAB 1.5% agarose gel. Gels were pre-stained with 
ethidium bromide, and observed under UV light. Photos were taken using the 
Aiphalmager 2200 (Alpha Innotech). 
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RNA gel electrophoresis 
RNA samples isolated using the All-in-One Purification kit were run on a 1.5% 
formaldehyde-agarose gel. The 2x RNA loading buffer (Norgen Biotek Corp.) contained 
ethidium bromide, eliminating the need for pre- or post-staining of the agarose gel. Five 
microlitres of each 50 JlL RNA elution (containing 5 JlL loading buffer) were heated to 
70°C for 15 minutes prior to being loaded onto the gel. 
RT-qPCR 
Reverse transcription 
Reverse tran~cription (RT) reactions were carried out on 2-500ng of RNA. In this 
reaction, 1 III of 100 mM of the reverse primer (Table 6) and 4 III of RNase free water 
, was added to make up a total volume of 5 Ill. The reaction mixture was first heated to 
70°C for 5 minutes, and while adding 15 III of RT reaction solution, it was cooled to a 
temperature of 4°C. The RT reaction consisted of 4 JlI of first strand buffer, 5.5JlI 
nuclease-free water, 0.5 JlI of dNTPs (50 JlM) and 0.1 JlI of Superscript III (Invitrogen). 
Following the chilling step, the reaction was incubated at 25°C for 5 minutes, at 42°C for 
90 minutes and then at 70°C for 15 minutes. Finally, it was kept at 4°C. 
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Table 6: list and sequence-of different RT-qPCR primers that have been used in this 
study. 
Primer 
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QuantitativePCR 
Using a known quantity of DNA template, or 2 fll of complementary DNA 
(cDNA), and the appropriate forward and reverse primers (Table 6), qPCR was 
performed according to standard protocol. Briefly, 20fll of the reaction mixture 
containing Norgen's PCR Mastermix (Norgen Biotek Corp.) spiked with 0.02% SYBR 
Green(10fll), reverse and forward primers (1.2fll each, 5flM stock) and dH20 (remaining 
volume) was cycled in Bio-Rad iCycler PCR machine. Initially, the DNA or cDNA was 
denatured at 95°C for 3 minutes, followed by 40 cycles of amplification. Each cycle had 
a melting phase (at 95°C for 15 seconds), annealing phase (at 59°C for 30 seconds) and 
polymerization phase (at 72°C for 1 minute). The reaction was then kept at 57°C for 1 
min, followed by melting curve analysis that was started over 80 cycles at a rate of 0.5°C 
. increment for every 10 seconds. A standard curve was then used for the quantification of 
DNA. 
miRNA Microarray 
miRNA mIcroarray expressIon analysis was performed on 5 flg of miRNA 
isolated using the All-in-One Purification Kit (Norgen Biotek Corp.). Isolated miRNA 
from HI688 and H164 cells as well as H522 and A549cells were pooled together to 
represent the two types of lung cancer, SCLC and NSCLC, respectively. The samples 
were sent to LC Sciences (Houston, TX), where miRNA micro array analysis was 
performed. The miRNA expression profile was done for the miRNA pooled SCLC and 
NSCLC samples against the miRNA isolated from the normal lung cell by LC Sciences 
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microarray application. The-array covered all miRNA transcripts that were available in 
the most recent version of the Sanger miRBase database (Version 17). 
In total, 1719 unique mature human miRNAs were tested. The protocol has been 
described previously by Chow et al. (2010). Briefly, miRNAs from the normal lung cell 
line were labeled with the dendrimer fluorescent dye (Cy3) while the miRNA isolated 
from the lung cancer cells were labeled with the CyS fluorescent dye. The tagged 
miRNAs were then hybridized on the dual-channel JlParaflo™ microfluidic chip, with 
each detection probe consisting of chemically modified nucleotide-coding segments 
complementary to the ta~get microRNA, as well as a spacer segment of polyethylene 
glycol used to extend the coding segment away from the substrate. Dye switching was 
also performed to eliminate any dye bias. Fluorescence images were collected using the 
laser scanner GenePix 4000B (Molecular Devices, Sunnyvale, CA) and digitized using 
Array-Pro image analysis software (Media Cybernetics, Bethesda, MD). 
The data were analyzed using a LOWESS (locally weighted regression) method. 
This involved background subtraction, and then normalization of the signals to balance 
the intensities of the Cy3 and CyS labeled transcripts so that differential expression ratios 
can be calculated. The normalization also removes system-related variations, including 
sample amount and signal gain differences of scanners. The ratio of the two sets of 
detected signals [log2 (cancer/normal)] and p values of the t test were calculated, and 
differentially detected signals were those with a p value <O.OS. At least SO% of the 
repeating probes had to produce signals above the detection level in order for the signal 
to be considered positive. A positive signal was plotted as a red spot in a cluster heat 
map. 
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Bioinformatics Data Analysis 
Quantitative PCR measures the expression of a specific gene and expresses its 
value in Cycle threshold (Ct). Ct is a relative value that corresponds to the cycle number 
at which the amount of the amplified DNA achieves the detection threshold level. 
Differential expression is done by comparing the normalized Ct values (.6.Ct) of all the 
biological replicates between two groups of samples (two biological conditions). 
The amount of DNA is nearly duplicated in every PCR cycle, therefore high Cts 
represent low expression (i.e. low concentration of the target molecule) while highly 
expressed genes have low Cts. Comparing the normalized expression (.~Ct) of the two 
conditions it is possible to calculate the fold change of the expression (-~~Ct). The fold 
change is the expression ratio, where up-regulated genes are represented by positive fold 
change while down-regulated genes are represented by a negative fold change (Livak and 
Schmittgen 2001). 
The fold change was calculated using the equation: 
2-~Ct (target miRNA) lung cancer cells / 2-~Ct (target miRNA) normal control. 
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RESULTS 
This study was focused on evaluating the changes in gene expression between 
lung cancer cells and normal lung cells. In order to achieve this goal, DNA methylation 
of certain genes as well as a miRNA expression profile has been investigated. Four 
established lung cancer cell lines were used; two SCLC (HI688 and H164) and two 
NSCLC (H522 and A549). A normal lung cell line CCD-8LU was used as a control. 
Nucleic acids were also isolated from HEK-293 cells and HeLa cells as a positive 
control. Quantification took place using the NanoVue™ spectrophotometer and the 
integrity was confirmed by gel electrophoresis. The purity of isolated nucleic acids was 
assessed by analyzing the ratio of absorbance at 260 nm to 280 nm (A2601 A28o) which was 
given by spectrophotometer. Genomic DNA was loaded on 1 % agarose gel to check its 
quality (Figure 3). The quantity of DNA varied sample to sample, with no signs of 
degradation (i.e. smearing). 
Figure 3: Agarose gel showing the DNA isolated from normal lung cell and lung cancer 
cells; HI688, H164, H522, A549 and CCD-8LU. DNA isolated from 293 and HeLa cells 
were used as a positive control. FR: Norgen's FastRunner DNA ladder. 
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RNA was loaded on 1.5% formaldehyde agarose gel to determine quality (Figure 
4). The gel displayed the two expected bands representing the 18S and 26S ribosomal 
RNA. None of the samples showed evidence of degradation, which would have been 
evident by smearing. In general, the 26S should always appear to be ~ 2 times brighter 
than the 18S band on the gel. RNA degradation causes this to shift, biasing the 
concentration of RNA towards the 18S ribosomal band. 
265 
18S 
Figure 4: A1.5% formaldehyde agarose gel showing the 28S and 16S subunits of RNA 
isolated from normal lung cell and lung cancer cells; HI688, H164, H522, A549 and 
CCD-8LU. RNA isolated from 293 and HeLa cells were used as a positive control. All 
lanes contain high quality RNA, with no signs of degradation. 
miRNA Integrity Evaluation 
The miRNA was isolated and the quality was confirmed on 1.5% formaldehyde 
agarose gel (Figure 5) and by RT-qPCR using the housekeeping gene 5S rRNA (Figure 
6). The gel showed that the quantity and the quality of the miRNA was high in all 
samples. RT -qPCR demonstrated successful amplification of 5 S rRNA in all samples. 
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miRNA 
Figure 5: A 1.5% formaldehyde agarose gel showing the miRNA isolated from normal 
lung cells and lung cancer cells; HI688, H164,H522, A549 and CCD-8LU. miRNA 
isolated from 293 and HeLa cells were used as positive controls. 
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Figure 6: Graph showing the results of RT-qPCR amplification of the gene 58 rRNA 
from the cells HI688, H164, H522, A549 and the normal control. - Normal control, -
8CLC, - N8CLC, - No template control. 
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DNA Methylation -
In this study the methylation pattern of certain genes related to lung cancer were 
investigated. Moreover, differential expressions of miRNA in lung cancer cell lines as 
well as a normal lung cell line were investigated by microarray. Methylation-sensitive 
restriction enzymes were used to determine the methylation status in certain genes 
related to lung cancer. This method relies on using an enzyme which either digests only 
methylated (Dpnl) or non-methylated (HpaJJ and Hhal) sites. The digested DNA was 
then purified using Norgen's Enzymatic Reaction Clean-Up Kit according to the 
manufacturer's protocol, and the purified DNA was used as template to amplify five 
genes, GAPDH, RASSFIA, RAR-B and TP53. 
peR products amplified from the DpnI-digested DNA 
DNA digested with the restriction enzyme Dpnl were used to test the methylation 
in the promoter region of GAPDH (which was found to be non-methylated) (Figure 7) as 
a control, and the promoter region of tumour suppressor genes RASSFIA and RAR-B 
(Figures 8 and 9). GAPDH was detected in all (digested and undigested) samples, 
indicating good DNA quality with no PCR inhibition. This was found even after DNA 
digestion and after the cleaning procedure (Figure 10). The tumour-suppressor genes 
RASSFIA and RAR-B were detected in all samples (digested and undigested) indicating 
that they were not methylated in any of the lung cancer cells that were tested (Figures 11 
and 12). 
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Figure 7: Map of the house keeping gene GAPDH (promoter region) showing no 
digestion sites for the enzyme Dpnl. 
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Figure 8: Map of the promoter region of the TSG RASSFIA showing one digestion site 
for the enzyme Dpnl. 
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Figure 9: Map of the promoter region of the TSG RAR-B with six digestion sites for the 
enzyme Dpnl. 
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Figure 10: The methylation profile of GAPDH as an internal control before and after 
digestion with Dpnl from lung cancer cell lines. U= uncut, C= cut. The size of the 
amplicon is 150 bp. (M= Norgen's FastRunner DNA marker). 
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Figure 11: The methylation profile of RASSFIA before and after digestion with Dpnl. 
The size of the amplicon is 250 bp. (U=Uncut, C=Cut, M= Norgen's FastRunner marker). 
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Figure 12: The methylation profile of RAR-~ before and after digestion with Dpnl. The 
size of the amplicon is 432 bp. (U=Uncut, C=Cut, M= Norgen FastRunner marker, C= 
No template control). 
peR products amplified from HpaII- and HhaI-digested DNA 
The methylation of GAPDH (Figure 13) and the promoter region of the tumour 
suppressor genes RAR-B and TP53 (the p53 gene) (Figure 14 and 15) was studied. 
GAPDH was detected in all digested samples showing good DNA quality (Figure 16). 
The TSG RAR-B did not give any amplification, indicating that it was not methylated. 
This supports the findings from Dpnl digestion (Figure 17). However, p53 was 
methylated in H164 and A549 cell lines, as appeared from the PCR amplification (Figure 
18). 
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Figure 13: Map of the house keeping gene GAPDH (promoter region) showing no 
digestion sites for the enzymes HpaJJ and Hhal 
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Figure 14: Map of the promoter region of the TSG RAR-B with two digestion sites for 
the enzyme HpaJl. 
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Figure 15: Map of the promoter region of the TSG TP53 showing one digestion site for 
the enzyme HpaJJ and three digestion sites for the enzyme Hhal. 
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Figure 16: The methylation profile of GAPDH as an internal control after digestion with 
HpaII and HhaI among control patients. The size of the amplicon is 150 bp. (PS= 
Norgen' s PCR Sizer DNA marker). 
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Figure 17: The methylation profile of RAR-~ before and after digestion with HpaII and 
Hhai. The size of the amplicon is 432 bp. (U=Uncut, C=Cut, M= Norgen's FastRunner 
DNA marker, NTC= No template control). 
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Figure 18: The methylation profile of TP53 before and after digestion with HpaJJ and 
Hhal. The size of the amplicon is 824 bp. (U=Uncut, C=Cut, M= Norgen's FastRunner 
DNA marker, NTC= No' template control). 
miRNA Microarray Expression Profiles 
Isolated miRNA from HI688 and H164 cells as well as H522 and A549 cells were 
pooled together to present the two types of lung cancer, SCLC and NSCLC, respectively. 
The miRNA expression profile was done for the miRNA pooled SCLC and NSCLC 
samples against the miRNA isolated from the normal lung cell line. Samples were sent to 
LC Sciences (Houston, TX). Nearly 1720 unique mature human miRNAs were tested. 
There were 79 miRNAs reported to be up- or down-regulated in lung cancer cell lines. 
Table 7 shows the miRNAs that were found to be the most significant in terms of fold 
difference. 
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Table 7: miRNA p-values and fold changes among normal, SCLC and NSCLC samples. 
Normal SCLC NSCLC 
Reporter Name p-value Mean Mean Mean 
hsa-miR-92a 1.51 x10-5 1,468 4,327 3,450 
hsa-miR-92b 1.65x 10-4 248 1,199 1,398 
hsa-miR-192 3.53 x10-4 149 1,861 1,325 
hsa-miR-183 7.23 x10-4 64 669 980 
hsa-miR-199a-3p 7.19x 10-4 2,248 2 5 
hsa-miR-214 4.01 x 10-4 878 12 9 
hsa-miR-145 1.29x 10-3 1,176 27 9 
-
hsa-miR-143 5.38 x10-J 831 10 3 
hsa-miR-425 8.68 x10-3 221 1,057 1,048 
hsa-miR-182 2.97x10-J 168 1,075 2,384 
hsa-miR -191 5.35 x 10-3 1,841 6,886 5,234 
hsa-miR-214 4.01 xl0-4 878 12 9 
hsa-miR-26b 9.91 xI 0-3 231 1,025 1,779 
hsa-miR-29a 4.35 xl0-3 11,313 215 4,687 
To further analyze these results, each type of cancer was compared with the 
normal lung sample. First, the fold change between the normal and the SCLC samples 
were calculated (Table 8). Most of the significantly expressed miRNA were down-
regulated in SCLC; this included miR-5096, miR-4484, miR-100, miR-22, miR-4454, 
miR-145and miR-29a, whereas, miR-92a and miR-181a were up-regulated (Figure 19). 
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Figure 19: Heat map ofmiRNA expression in SCLC and normal lung control. The green 
colour indicates the miRNAs that are down-regulated in the SCLC sample relative to the 
normal sample, and the red colour indicates the miRNAs that are up-regulated in the 
SCLC sample relative to the normal sample. 
Table 8: miRNA p-values and the fold changes among normal and SCLC samples. 
Normal (1) SCLC (2) Log2 (2/1) 
Reporter Name p-value Mean Mean 
hsa-miR-5096 6.54x10-4 1,201 336 -1.84 
hsa-miR-92a 5.64x10-3 1,468 4,327 1.56 
hsa-miR-4484 6.11 xl 0-3 4,812 679 -2.83 
hsa-miR-100 6.21 xl O-J 4,718 4 -10.40 
hsa-miR-22 6.22x10-J 823 305 -1.43 
hsa-miR-4454 7.49x 10-3 10,363 445 -4.54 
hsa-miR-145 8.46x 1 0-3 1,176 27 -5.42 
hsa-miR-181a 8.83 x 10-3 361 536 0.57 
hsa-miR-29a 9.36x10-J 11,313 215 -5.72 
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Second, the fold ch~nge was calculated for normal and the NSCLC sample (Table 
9). miR-4497 and miR-22 were down-regulated in NSCLC (Figure 20). 
In addition, some miRNAs were up- or down-regulated in one type of cancer 
more than the other (Table 10). After estimating their fold change, most of them were 
more up-regulated in NSCLC than SCLC: miR-222, miR-221 miR-99b miR-125a-5p and 
mir-29c. miR-4497 was shown to be up-regulated in SCLC (Figure 21). 
Table 9: miRNA p-values and the fold changes among normal and NSCLC. 
Reporter Name p-value 
hsa-miR-4497 5.55x 1 0-3 
hsa-miR-22 6.82x 10-3 
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Figure 20: Heat map of miRN A expression in the NSCLC sample and normal control. 
The green colour indicates the miRNAs that were down-regulated in the NSCLC relative 
to the normal sample, and red colour indicates the miRNAs that are up-regulated in 
NSCLC relative to the normal sample. 
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Figure 21: Heat map of miRNA expression in SCLC and NSCLC samples. The green 
colour indicates the miRNAs that were down-regulated and red colour indicates the 
miRNAs that are up-regulated. 
Table 10: miRNA p-values and fold changes among SCLC and NSCLC samples. 
SCLC (1) NSCLC (2) Log2 (2/1) 
Reporter Name p-value Mean Mean 
hsa-miR-222 2.99xl0·j 267 4,485 4.07 
hsa-miR-99b 4.04xl0·3 18 1,172 6.03 
hsa-miR-125a-5p 6.00xl0·3 4 2,331 9.02 
hsa-miR-221 6.90xl0·'; 102 4,035 5.30 
hsa-miR-29c 8.93 x 10·'; 16 604 5.21 
hsa-miR-4497 9.24x 10·j 3,331 449 -2.89 
hsa-miR-125b 9.57xl0·j 81 8,068 6.65 
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Validation of miR-100, miR-221, miR-199a-3p and miR-182 deregulation 
anlong lung cancer and normal lung eel/lines using RT-qPCR 
Several deregulatedmiRNAs were up-regulated in lung cancer cell lines 
compared to the normal control, such as miR-182, or down-regulated, such as IniR- IOO, 
miR-22 1 , and miR-199a-3p. These miRNAs are already known to have a role in 
developing cancer. Therefore, their expression level was tested among lung cancer and 
normal lung cell lines, and was nonnalized against the housekeeping gene 5S rRNA to 
evaluate their potential as lung cancer bionlarkers (Figure 22). The fold-difference of the 
gene expression was calculated by using the equation 2-ilCt (target miRNA) lung cancer cells / 
T ilet (target miRNA) normal control. The p-value must be <0.05 and the expression has to be 
more than three-fold difference to be considered significant (Table 11). 
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Figure 22: The amplification 5S rRNA from the normal and lung cancer cell lines. The 
5SrRNA was used for normalization. - Normal control, - SCLC, - NSCLC, -
No template control. 
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Table 11: The p values and fold-difference for the expression of miR-I00, miR-221, 
miR-199a-3p, and miR-182 among lung cancer cell lines using RT-qPCR. 
H1688 H146 H522 A549 
miR-IOO and miR-199a-3p were down-regulated and miR-182 was up-regulated 
in both lung cancer types (SCLC and NSCLC). miR-221 was down-regulated in one of 
SCLC cell lines (HI688) and one of NSCLC cell lines (A595). However, trends toward 
up- and down-regulation were observed in NSCLC (H522) and SCLC (H146), 
respectively. Figure 23 shows the fold difference in expression among the four miRNAs, 
relative to the normal control, and Figure 24 shows the quantitative real-tilne PCR 
amplification results. 
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Figure 23: The fold difference for the expression of the deregulated miRNAs (miR-199a-
3p, miR-182 miR-lOO and miR-221) in the lung cancer cell lines relative to the normal 
control. Fold difference was calculated using the equation 2-tlCt (target miRNA) lung cancer 
cells / 2-tlCt (target miRNA) normal control. The data represent average of 
triplicate experiments. 
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Figure 24: Real-time PCR quantitative curve showing the amplification of the 
deregulated miRNAs in the lung cancer cell lines and the normal control. The 5SrRNA 
was used for normalization. The experiment was carried out in triplicate to avoid any 
reading error from the PCR machine. - Normal control, - SCLC, - NSCLC, - No 
template control. 
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Validation ofmiR-100,-miR-221, miR-199a-3p and miR-182 mRNA targets 
k '1 for the genes FGFR3, P27 PI, c-met and RGS17 among lung cancer samples 
using RT-qPCR 
Targets of the three down-regulating miRNAs (miR-100, miR-221 and miR-199a-
3p) and for the up-regulated miRNA (miR-182) were studied because they have been 
known to have a role in developing cancer. To evaluate the mRNA level of these target 
genes, their expression was evaluated in lung cancer cell lines and normal cells by using 
RT-qPCR. The selected genes were nonnalized against the housekeeping gene 5SrRNA. 
The fold difference in gene expression and the p value for the four target genes are shown 
in Table 12, 
Table 12: The p values and fold difference for the expression of genes FGFR3, P27kpi1, 
c-met and RGS 17 among lung cancer cell lines using RT -qPCR. 
H1688 H146 H522 A549 
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miR-IOO was dOWll:-regulated in the SCLC cell line, compared to normal controls, 
therefore the mRNA for their target gene was expected to be up-regulated. FGFR3 
mRNA was up-regulated in the SCLC cells and one NSCLC cell line (A549), as 
predicted. Whereas, it was detected to be low in one NSCLC cell line (H522). Figure 25 
shows the amplification result from the R T -qPCR, and the fold difference in expression 
level among SCLC cells and NSCLC cells relative to normal cells can be found in Figure 
26. 
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Figure 25: The QPCR quantification curve for FGFR3 mRNA amplification from two 
SCLC cell lines, two NSCLC cell lines, and one normal control. - Normal control, -
SCLC, - NSCLC, - No template control. 
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Figure 26: The fold change in expression level ofFGFR3 in lung cancer samples (SCLC 
and NSCLC) relative to normal cells. Fold difference was calculated using the equation 2-
ilCt (target mRNA) lung . cancer cells / 2-ilCt (target mRNA) nornlal control. The 
data represent average of triplicate experiments. 
Some miRNA expression could be used to distinguish SCLC from NSCLC. IniR-
221 expression was up-regulated in NSCLC cells, and down-regulated in SCLC cells. 
Therefore, the target gene P27kpi1 ought to have different expression levels among lung 
cancer types. P27kpil mRNA was found to be up-regulated in one SCLC cell line 
(H1688), and down-regulated in (H146), whereas it was found to be down-regulated in 
both NSCLC cell lines. Figure 27 shows the amplification result from the RT-qPCR, and 
the fold difference in expression level among SCLC and NSCLC cells relative to normal 
cells can be found in Figure 28. 
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Figure 28: The expression level of P27 kip! in lung cancer cell lines, SCLC and NSCLC, 
as compared to the normal cell line. Fold difference was calculated using the equation 2-
L!Ct (target mRNA) lung cancer cells / 2-L!Ct (target mRNA) nonnal control. The 
data represent average of triplicate experiments. 
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The miRNA, miR .. :.199a-3p, were down-regulated in both types of lung cancer. 
One of this miRNA's target genes is c-Met. The 11lRNA for this gene was down-regulated 
in both SCLC cell lines and one NSCLC cell lines (H522), but up-regulated in the other 
NSCLC cell line (A549). The aInplification result of the RT-qPCR and the fold change of 
the expression can be found in Figures 29 and 30. 
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Figure 29: The PCR quantification curve for the c-Met mRNA amplification from two 
SCLC, two NSCLC and one normal control cell line. - Normal control, - SCLC, -
NSCLC, - No template control. 
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Figure 30: The fold change of the expression level of c-Met in lung cancer samples 
(SCLC and NSCLC) relative to the normal control. Fold difference was calculated using 
the equation 2:~Ct (target mRNA) lung cancer cells / T~Ct (target mRNA) normal control. The 
data represent average of triplicate experiments. 
On the other hand, miR-182 was up-regulated in all lung cancer cell types. 
RGS17 gene was known as one of miR-182 targets. This mRNA target was found to be 
down-regulated in one SCLC cell line (H146), whereas it was found to be up-regulated in 
NSCLC cell lines (H522 and A549) and one SCLC cell line (H1688). The amplification 
result of the RT -qPCR and the fold change of the expression can be found in Figures 31 
and 32. 
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Figure 31: The QPCR quantification curve for RGS17 mRNA amplification from two 
SCLC, two NSCLC and one normal cell line control. - Normal control, - SCLC, -
NSCLC, - No template control. 
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Figure 32: The fold change of the expression level of RGS 17 in lung cancer samples 
(SCLC and NSCLC) relative to the normal control. Fold difference was calculated using 
the equation 2-~Ct (target mRNA) lung cancer cells / T~Ct (target mRNA) nonnal control. The 
data represent average of triplicate experiments. 
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DISCUSSION 
Lung cancer is the leading cause of cancer-related deaths in Canada. Over 25,300 
new cases of lung cancer were reported in 2011, and 20,600 deaths. Lung cancer is more 
common in adults over 45 years of age, and cigarette smoking greatly increases an 
individual's risk of developing cancer. In fact, the risk of lung cancer is directly related to 
the number of cigarettes smoked per day. Many factors other than cigarette smoking 
influence an individual's odds of developing lung cancer, including exposure to asbestos, 
air pollution, carcinogens, radon gas, and more certain viruses, such as the Human 
Papillomavirus -(HPV), Simian virus, (SV) and Cytomegalovirus (CMV) have been 
proven to cause lung cancer in animals, and potentially in human beings. All these 
causative factors and exposures have the ability to cause mutations at both the genetic 
and epigenetic level, leading to a multi -step process of lung carcinogenesis that involves 
disturbance in cell growth, repair, and cell apoptosis (Brambilla et al., 2003). Mutations 
at the genetic level cause changes in the DNA sequence present in the tissues of the 
respiratory system. With increasing exposure to carcInogens, more tissue becomes 
damaged, and eventually cancer can develop. Often, cancer develops either due to the 
activation of an oncogene or due to the inactivation of a tumour suppressor gene (TSG) 
(Chung et al., 1995). 
For both men and women, lung cancer is known to be the deadliest type of cancer. 
The late diagnosis and strong metastatic potential of lung malignancies is considered to 
be the main reason that the prognosis of lung cancer is often grim, and that treatment 
options are limited at the time of diagnosis. Most lung cancer patients are diagnosed at a 
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later stage of cancer development, when the tumour has already metastasized. Treatments 
in later stages of lung cancer are rarely curative, and a full recovery is nearly impossible. 
Research has shown that if lung cancer could be diagnosed at an early stage before 
metastasis, the 5-year survival rate could be significantly increased to 60-80% 
(Dominioni et al., 2000). This clearly emphasizes the importance of early detection of 
lung cancers, as it would not only lead to a higher treatment success rate, but also 
decrease the lung cancer associated mortality rate. 
Realizing the importance of early detection of lung cancers, a lot of work has 
been done in this area qver the last few decades. In the same effort, there has been 
considerable interest in various molecular approaches to the diagnosis of lung cancer, 
with a particular interest in the discovery of lung cancer biomarkers. Cancer biomarkers 
have shown promising results in early cancer detection, as they can indicate physiological 
abnormalities (Fung et al., 2000) through non-invasive methods of detection, and can 
serve as good indicators of many areas of cancer biology. Their ability to improve the 
specificity of various imaging techniques currently in use has shown a strong diagnostic 
potential. Other than their use in diagnosis, they can also be applied in guiding the cancer 
therapy and following up the response to that therapy (Sung andCho, 2008). 
With the recent advancements in molecular biology and the development of 
revolutionary techniques like polymerase chain reaction (PCR) and micro array analysis, 
rapid and sensitive detection of lung cancer biomarkers has been made possible in the 
serum, sputum and exhaled air of a patient. This allows for non-invasive, rapid and early 
diagnosis with a high degree of sensitivity. Considering their diagnostic and prognostic 
value, certain potential biomarkers have been isolated for the detection of lung cancer. 
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However to date, no single biomarker has been standardized for the diagnosis of lung 
cancer. The present study was designed to discover and standardize a promising lung 
cancer biomarker by studying the aberrant methylation and miRNA profiling of lung 
cancer cell lines. 
DNA Methylation-Based Biomarker Approach 
Aberrant methylation is one of the most important epigenetic mechanisms that 
regulate gene expression, and it has a well-known role in developing cancer. Several 
intense investigations have been focused on these epigenetic modifications, which mainly 
occur in the promoter region of a tumour suppressor gene, leading to gene silencing 
(Feinberg, 2004). Considering the fact that these aberrant methylation changes occur 
early in the development of cancer, and that methylation can be easily detected in any 
bodily fluid sample, they were examined in this study for their potential use in the early 
detection of lung cancer. 
Studies have shown that some genes like RASSFIA and p16 are methylated in a 
number of cancers, while others are only methylated in a specific type of cancer (Das and 
Singal, 2004). Tsou et al. (2002) studied the gene alterations during lung cancers in 
detail, and they were able to detect at least 40 genes which showed some alteration in 
their methylation patterns. Among those 40 genes, RAR-B, RASSFIA, CDNK2A, 
CHD13, and APC were the most commonly hypermethylated (Tsou et al., 2002). Based 
on these findings, we selected two tumour suppressor genes, RASSFIA and RAR-B, to 
study their methylation profiles among four lung cancer cell lines (two SCLC and two 
NSCLC). From our results, we found that none of these genes were methylated. 
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The TSG RASSF1 is located on chromosome 3p. It has several transcripts, which 
only differ in their mRNA splicing and promoter selection. RASSF1A is one of the gene 
transcripts that is rarely found mutated in lung cancer. Burbee et ale (2001) tested the 
methylation of the promoter for RASSF1A in NSCLC and found that it was methylated 
in only 30% of 107 primary NSCLC cell lines. On the other hand, Dammann et ale (2001) 
tested its methylation status in 28 SCLC cell lines and found that it was methylated in 
79% (22 out of 28) of SCLC cell lines. These results seem to contradict our results, 
however it is worth mentioning that both the groups used different cell lines than what we 
used, and also they used . greater number of cell lines than the 4 cell lines used in our 
study. Methylation of this gene also indicates shorter overall survival and poor prognosis 
in stage I NSCLC (Tomizawa et al., 2002 and Burbee et al., 2001). Therefore, it could 
potentially be used as a prognostic marker. By comparing these findings with our results, 
it was evident that non-methylated RASSF1A gene may be an indication for the 
prognosis of our NSCLC cell lines. It has been found that while RASSF1A is often only 
hypermethylated in metastatic lung cancers, it is overall not an effective early lung cancer 
biomarker (Choi et al., 2005; Niklinska et al., 2009 and Schagdarsurengin et al., 2003). 
As RASSF1A was not found to be hypermethylated in our lung cancer ceUlines, and as it 
has not been found to be consistently methylated in other lung cancer cell lines, it could 
be concluded that the potentiality of RASSF 1A as a biomarker is limited to possibly 
monitoring the metastasis in already-diagnosed lung cancer patients (Niklinska et al., 
2009). 
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The function of the retinoic acid receptor ~-2 (RAR-~) gene has been found to be 
defective in lung cancer, therefore it is considered as a TSG. This gene is located on 
chromosome 3p24, and it has an important role in mediating various responses that 
control growth mechanisms (Lu et aI., 1997). The inactivation of this gene has been 
reported in heavy smokers and in NSCLC patients (Ayoub et aI., 1999). Virmani et al. 
(2000) found that RAR-~ is methylated in 62% of SCLC cell lines,and in 43% of 
NSCLC cell lines. In contrast to these findings, we did not find RAR-~ methylated in any 
of the cell lines we used. This may be due to the use of fewer cell lines (four) as 
compared to the previous studies where the authors have used large numbers of cell lines. 
Virmani et al. (2000) used 66 SCLC lines and 78 NSCLC lines and, as such, may have 
got more reproducible results as compared to our study in terms of gene methylation of 
the RAR-~. However, some authors have already raised doubt as to the use ofRAR-~ as 
a lung cancer biomarker, as its expression status is often inconsistent between normal and 
cancerous lung tissues (Chang et al., 2004). 
TP53 has been evaluated as the second inactivated TSG in lung cancer (the first 
being the retinoblastoma gene). TP53 is a gene which is commonly inactivated in a 
variety of malignancies; however the detailed study of its mutation pattern in these 
malignancies has shown that its mutation spectrum correlates with specific tumour types. 
Considering this fact, we chose to evaluate the aberrant methylation of TP53 in the four 
lung cancer cell lines under consideration, because methylation is one of the factors that 
may be involved in the inactivation of this gene. Literature has shown that methylation of 
this gene is not a widely studied phenomenon, and much effort has been directed towards 
the study of its mutation. Accordingly, most literature addresses the latter topic. Among 
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those which address the methylation of this gene, one was aimed at establishing an 
association between TP53 methylation and lung cancer risk (Woodson et al., 2001). 
Other literature covering TP53 mutations indicates that this is the most commonly 
observed genetic change in malignancies (Levine et al., 1991). Among lung cancers, 
TP53 is found to be mutated in 70% of SCLC cases, in 65% of the squamous type 
NSCLC, and in 33% of the adenocarcinomatous type ofNSCLC (Tessema and Belinsky, 
2008). Our results were similar to the results reported by previous studies. Our results 
revealed that TP53 can be methylated in both types of lung cancer cell lines, and in our 
case, this meant lout of 2 SCLC cell lines and lout of 2 of the NSCLC cells. 
With only one gene of interest (the TP53 gene) being found to have promoter 
hypermethylation in this study, and with the low sensitivities and specificities of other 
genes studied for aberrant methylation of these genes by other researchers, none of the 
genes used in this study were found to be useful as a lung cancer biomarker. Other 
authors have argued that it is highly unlikely that one single DNA methylation biomarker 
will be used on its own for lung cancer detection (Anglim et al., 2008). More research is 
needed in this area if DNA methylation is to be considered as a possible lung cancer 
biomarker in the near future. However, it should be noted that one methylation-detection 
technique is not considered the gold standard in aberrant methylation detection. For more 
reliable and consistent results, more than one methylation-detection technique is 
recommended to minimize false positives or negatives (Brena et at., 2006). 
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miRNA-Based Biomarker Approach 
miRNA are the small non-coding RNAs which negatively regulate gene 
expression (Cho, 2007). In a number of studies, these miRNAs have shown their 
individual roles in cancer development through the regulation of oncogenes, tumour 
suppressor genes or via loss/mutation of a miRNA gene. Recently it has been established 
that the expression patterns (or signatures) of miRNA genes are far more effective in 
characterizing the developmental origins of cancers than the mRNA expression 
signatures. On the basis of these findings,-miRNAs may serve as a potential diagnostic 
and prognostic tool for various human cancers (Tricoli and Jacobson, 2007). 
In humans, miRNAs act as regulatory proteins, inhibiting the expression of their 
target genes mainly at the level of protein translation. They rarely act on the messenger 
RNA to cause its degradation or cleavage (Bartel, 2004). These target genes are 
recognized by microRNAs on the basis of complementary sequence (Brennecke et aI., 
2005) and the complementary sites are usually present within the 3' -untranslated region 
of the target messenger RNA (Pillai et aI., 2007). As these complementary sites are not 
translated, the mature miRNAs are only partially complementary to their corresponding 
messenger RNAs, explaining why miRNAs infrequently act on mRNAs. 
When tumour cell lines were compared to those of normal tissues, miRNA 
expression was found to be widely deregulated in the former ones (Gaur et at., 2007), 
showing an association between deregulated miRN A expression and tumour 
development. It has also been observed that in human cancers, there is a global decrease 
in miRNA levels, indicating that these microRNAs may have some role in tumour 
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suppression within the human body (Lu et al., 2005). This association between the 
widespread reduction in miRNA expression and tumorigenesis was first reported by 
Kumar et al. (2007). Kumar et al. (2007) carried out a study in mice and human cells 
simultaneously, in which the miRNA-processing enzymes Drosha and Dicer were 
knocked out to produce a widespread reduction in miRNA expression. These cells with 
globally reduced miRNA showed enhanced cellular growth in vitro and produced faster 
growing and more invasive tumours when injected into nude mice (Kumar et al., 2007). 
Considering these findings, we aimed to study the miRNA profile in normal and lung 
cancer cell lines, and assess their potential as a biomarker for lung cancer. 
Interestingly, our miRNA micro array results showed that 80 miRNAs were 
significant! y deregulated in lung cancer cell lines in comparison to the normal lung cell 
line control. Of these deregulated miRNAs, four miRNA (miR-199a-3p, miR~182, miR-
100 and miR-221) were selected for further analysis based on their putative targets and 
high expression levels. The validation of these miRNA using RT -qPCR complemented 
the microarray results. Our study was the first to indicate that hsa-miR-4301, hsa-miR-
4707-5p and hsa-miR-4497 (newly discovered miRNA) are deregulated in lung cancer 
cell lines. To validate their role in lung cancer, further studies should be carried out to 
find out possible targets for these miRNAs. Our study remaines inconclusive, as we 
didn't report any kind of target for these miRNAs and hence we recommend further 
extensive studies on these newly discovered miRNAs. 
miR-199a-3p is a miRNA whose expression is found to be deregulated in some 
cancers. It is found to be over-expressed in some tumour cells, such as breast cancer cells, 
while it is under-expressed in other tumour cells (Shatseva et al., 2011). It is under 
81 
Hadeel Zamakhshari Lung Cancer Biomarker 
-
expressed in many human malignancies including lung cancer, and studies have shown 
that its exogenous expression can reduce the motility and viability of melanoma, gastric, 
and lung cancer cells (Migliore et al., 2008). Upon restoration of the attenuated levels of 
miR-199a-3p in cancer cells, cells demonstrated decreased growth and proliferation via 
G(l)-phase cell cycle arrest and increased sensitivity to doxorubicin-induced apoptosis 
(Fornari et al., 2010). The miR-199a-3p is known to target the mammalian target of 
rapamycin (mTOR) and proto-oncogene c-MET in cancers (Fornari et al., 2010). The 
mTOR pathway is involved in the phosphorylation of phospho-p70S6 kinase enzyme, the 
regulation of protein synthesis, cell proliferation and it also allows G1-S progression in 
the cell cycle. A causal link has been hypothesized between miR-199a-3p and mTOR 
because the under-expression of miR-199a-3p in many tumour cells is associated with 
over-expression ofmTOR (Fornari et al., 2010). 
The c-Met proto-oncogene is involved in a complex process of invasive growth 
that involves excessive cell motility, invasion, and decreased apoptosis (Comoglio and 
Trusolino, 2002). Recent studies have shown that miR-199a-3p directly targets the c-Met 
proto-oncogene in melanoma, gastric and lung cancer cells, as well as extracellular 
signal-regulated kinase 2 (ERK2) (Kim et ai., 2008), Exogenous miR-199a-3p has been 
found to decrease the invasiveness of the tumours by 60% (Fornari et al., 2010). 
In our study, the levels of miR-199a-3p were found to be down-regulated in the 
lung cancer cell lines in accordance with the previously published literature, however its 
putative target c-Met was not found to be up-regulated, except in the case of one lung 
cancer cell line. This could be due to the fact that miRNA target recognition can be 
changed depending on their function in a specific locale (Lin and Ganem, 2011). Also, 
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there are some factors known to regulate the selection of target genes, but these factors 
are still under investigation (Bartel, 2009). 
The first study carried out to establish a link between miR-182 and lung cancer 
was done by Cho et al. (2009). In this study, the clinical parameters of the patients 
suffering from lung cancer were correlated with the plasma levels of 3 miRNAs: miR-
155, miR-197 and miR-182. A detailed account of the history and patient profile 
including sex, age, and smoking history indicated that there was no significant 
association between the levels of these three miRNAs and the history, stage of the cancer 
or histological type oftu~our. However, the plasma levels of two miRNAs, miR-155 and 
miR -197, but not miR -182, were found to be significantly higher in the patients with 
metastasis than in those without metastasis. The patients were then grouped on the basis 
of stage of lung cancer. The levels of all three miRNAs were not significantly different 
between the stages, nor did they corresponded with the severity of the disease. However, 
all patients invariably had significantly elevated plasma miR-155, miR-197, and miR-182 
levels when compared with those of the cancer-free controls (Zheng et aI., 2011). 
In lung tumours, the expression of a gene called RGS 1 7 belonging to the RZ 
subfamily of the Regulators of G-protein signalling (RGS) family is also found to be 
deregulated. RGS17 is a protein that activates GTPase (GAPs) and thus stops the activity 
of G-proteins, negatively regulating the signalling of G-protein coupled receptors 
(GPCRs) (Nunn et aI., 2006). A study carried out by James et al. (2009) identified that 
expression of this gene was up-regulated in almost 80% of lung tumours. Another study 
was carried out by Sun et al. (2010) that aimed to study the relationship between the 
expression levels ofhsa-miR-182 and RGS17 in human lung cancers. They showed that a 
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reverse correlation existed in the hsa-miR-182 and RGS17 level between the normal lung 
cell line and the lung cancer cell line in 50% of cases, however, the data was not 
significant (r = -0.209, P = 0.563) (Sun et aI., 2010). 
In agreement with this literature, our results have shown that miR-182 was found 
to be up-regulated in the microarray and RT -PCR results and its putative target was only 
down-regulated in one of the SCLC cell lines (H 146). The findings of the present study 
were similar to the results reported by Sun et al. (2010) which found that RGS 17 can be 
targeted by miR -182 but not in all lung cancer cases. 
miR-1 00-is a miRNA which has been found to be down-regulated in many cases 
of lung cancer (Wang et al., 2009 and Gao et at., 2010). However, the results of Garofalo 
- et al. (2008) indicated that miR-100 was dramatically over-expressed (five- to eight-
fold) in several NSCLC cell lines. Studies indicated that miR-100 is a tumour suppressor 
gene (Nagaraja et aI., 2010) that targets FRAPlImTOR and FGFR3 in several cancers 
(Catto et at., 2011 and Henson et al., 2009). FGFR3 belongs to a family of trans-
membrane receptors called the fibroblast growth factor receptor (FGFR) family, and 
plays a key role in the process of angiogenesis and embryonic development (Passos-
Bueno et al., 1999). Mutations or changes in the expression of FGFR3 are implicated in 
certain tumour types including lung cancer. 
With this overvIew, we evaluated the expreSSIon of miR-100 and its target 
FGFR3. Our results showed that the expression of miR-100 was down-regulated in our 
NSCLC and SCLC cell lines and their target gene was up-regulated in most of the cancer 
cell line as expected. 
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miR-221 is an oncogenic miRNA which has shown deregulated expression in 
certain cancer types. Studies carried out on the expression of miR -221 in lung cancer 
cells has shown that they are up-regulated in certain subtypes of lung cancer (Seike et al., 
2009 and Garofalo et al., 2008) but they are down-regulated to a significant level in the 
SCLC type of lung cancer (Du et al., 2010). 
The published literature has shown that miR-221 targets the receptor tyrosine 
kinase Kit and the cyclin-dependent kinase (cdk) inhibitor, p27kipl (Felli et al., 2005 and 
He et al., 2005). p27 kip 1 , in its normal state binds to the cyclin/cyclin-dependent kinase 
complexes and inhibits their function, thereby blocking the progression of the cell cycle. 
Thus p27 kip! operates at the heart of the cell cycle (Philipp-Staheli et al., 2002) and 
deregulated miR-221 expression contributes to the growth and progression of tumour 
cells by blocking p27 kipl mRNA translation (Galardi et al., 2007). 
For miR-221, our results showed that it could be a putative biomarker to 
distinguish between the two types of lung cancer because it was down-regulated in SCLC 
cell lines and up-regulated in NSCLC cell lines. Further studies should be conducted in 
non-invasive samples from lung cancer patients to truly assess the ability of miR-221 to 
predict cancer type, and to determine the sensitivity and specificity of this potential 
biomarker. miR-221 targets the gene p27 kipl in only two cell lines. This could be a result 
of a selective pressure which allowed the target gene to be expressed where the miRNA 
could be found (Farh et al., 2005). In addition, cells may be selecting another miRNA as 
their partner because recent studies reported the target gene can also choose their partners 
to the same extent as the miRNA itself (Hofacker, 2007). 
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miRNAs represent an important resource for diagnostic and prognostic 
biomarkers for lung cancer, as their expression has been found to be linked to the origin 
and state of tumours, as well as other pathological variables. miRNAs are also very small, 
making them stable and resistant to RNase degradation (Kim do et al., 2007), a common 
problem in many biological fluids, such as plasma. To further understand the role of 
miRNA in cancer, extensive research is consistently being done involving the role of 
miRNAs on gene regulatory pathways, as well as determining the miRNA's mRNA 
targets, and the impact of miRNAs on protein expression levels (Paranjape et al., 2009). 
The use of miRNAs in the screening of high-risk individuals or to monitor disease 
recurrence in post-treatment cancer patients is a realistic biomarker approach, and with 
the use of large clinical trials, one can assume miRNAs will become commonplace in the 
screening and monitoring of lung cancer in the near future. 
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CONCLUSIONS 
DNA methylation 
The aberrant methylation of CpG islands located within the promoter regions of 
three tumour suppressor genes (RASSFIA, TP53 and RAR-~) was studied using 
methylation sensitive restriction enzyme PCR. DNA was isolated from four different lung 
cancer cell lines as well as the normal lung cell line, was digested with DpnJ or 
HpaJIHhaJ, and followed by end-point PCR. All the tested genes were amplified before 
and after digestion. GA~DH, as an internal control, was amplified before and after 
digestion. Based on the results of this study, the following can be concluded: 
1. The RASSFIA and the RAR -~ tumour suppressor genes were not found to be 
hypermethylated among all the tested lung cancer cell lines. 
2. The TP53 tumour-suppressor gene was found to be hypermethylated in the H164 
and A549 whereas it was not found to be hypermethylated the H1688 and H522 
lung cancer cell lines, compared to the normal lung cell lines. 
3. Agreeing with the literature, our result show that TP53 was methylated in 50% of 
the lung cancer cell lines (one NSCLC cell line and one SCLC cell line), whereas 
the RASSFIA and RAR-~ tumour-suppressor genes were not significantly 
methylated in any lung cancer cell lines. 
4. Future research should focus on studying the methylation status of a panel of 
TSGs and oncogenes, as the sensitivities and specificities of anyone single 
aberrant-methylated gene are too low for clinical use. 
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miRNA microarray 
The second part of the study involved a micro array analysis of miRNA isolated 
from all four cancer cell lines, as well as the normal lung cell line. The miRNA 
expression profile was done for the miRNA pooled SCLC and NSCLC samples against 
the miRNA isolated from the normal lung cells. In total, 1719 unique mature human 
miRNAs were tested. After normalization, tests were conducted and p values generated 
into a heat map containing all deregulated miRNAs (both up- and down-regulated) as 
compared to the normal lung cell line control. Based on these results, the following can 
be concluded: 
1. Microarray results showed that the expression of 70 different miRNAs was 
significantly de-regulated in the lung cancer cell lines in comparison to the 
normal control cell lines. According to the analysis of the putative targets of 
these 70 miRNAs, four miRNA candidates were chosen for further analysis 
(miR-I00, miR-199a-3p, miR-182 and miR-221). According to the literature, 
the putative targets of the miRNA under study had a relation with the 
progression and/or control of the development of cancer. 
2. The differential expression of the miRNA candidates were validated using 
RT-qPCR and agreed with the microarray results. The putative targets for the 
candidate miRNAs were also validated using RT-qPCR (up-regulated miRNA 
= down-regulated putative target). 
3. miR-199a-3p and miR-I00 were down-regulated, whereas miR-182 was up-
regulated in both the micro array and RT -qPCR results. 
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4. Agreeing with the literature, the expression of miR-22l was found to be 
down-regulated in the SCLC lung cancer cell lines as compared to NSCLC; 
5. According to our results, miR -100 was found to be a TSG since it targets 
FGFR3 that plays a critical role in the development of cancer (oncogene). 
6. Our study was the first to indicate that hsa-miR-4301, hsa-miR-4707-5p and 
hsa-miR-4497 are deregulated in lung cancer cell lines. The targets of these 
miRNA are unknown, and future research should focus on determining if 
these miRNA have putative targets relating to the development of lung cancer, 
or if they were down-regulated, to determine if their targets involve normal 
cell growth and differentiation. 
7. The future of diagnostic medicine may involve the use ofmiRNA biomarkers 
as they are consistent, reliable, and stable in biological fluids, making them 
prime candidates for non-invasive screening of high-risk groups or post-
treatment cancer patients. 
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